Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

SL Science Holding Ltd

CIK 2070534Updated Nov 22, 2026

SLBT price & chart

Provider market data

Loading TradingView…

NASDAQ:SLBT on TradingView ↗

TradingView · Data may be delayed

About the company

SL Science Holding Limited is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, the Company hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Science aims to create cellular therapies that we believe have the potential to revolutionize the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry. For more information, please visit the Company's website at: https://www.slbtgroup.com/ and follow SLBT on X, LinkedIn, FB, IG and Threads.

6-K · 2026-07-10 · 0001104659-26-082459

Company description from the cited filing.

In the news

No coverage from other publishers is available.

Seeking Alpha

Recent filings

  1. 424B3 filing

    424B3 · 2026-11-20 · 0001104659-26-130598

  2. 6-K filing

    6-K · 2026-11-03 · 0001104659-26-122005

  3. 6-K filing

    6-K · 2026-10-26 · 0001104659-26-118805

  4. S-8 filing

    S-8 · 2026-10-09 · 0001104659-26-115047

  5. 6-K filing

    6-K · 2026-09-24 · 0001104659-26-110392

Show 5 more recent filings
  1. 6-K filing

    6-K · 2026-09-01 · 0001104659-26-104331

  2. 6-K filing

    6-K · 2026-08-27 · 0001104659-26-102108

  3. 424B3 filing

    424B3 · 2026-08-14 · 0001104659-26-096560

  4. EFFECT filing

    EFFECT · 2026-08-12 · 9999999995-26-002644

  5. F-1 filing

    F-1 · 2026-07-31 · 0001104659-26-089195

Offerings

Registration 333-297881

F-1 · 2026-07-31 · 0001104659-26-089195

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

slbt-20260630xex99d1.htm · 6-K · 2026-10-26

Table of Contents Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF SL SCIENCE HOLDING LIMITED AND SUBSIDIARIES Consolidated Balance Sheets as of June 30, 2026 (Unaudited) and December 31, 2025 F-2 Unaudited Interim Consolidated Statements of Operations and Comprehensive (Loss) Income for the six months ended June 30, 2026 and 2025 F-3 Unaudited Interim Consolidated Statement…

6-K · 2026-10-26 · 0001104659-26-118805

Read attachment ↗
slbt-ex99d2.htm · 6-K · 2026-10-26

Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS References in this report (this “Report”) to “we,” “us” or the “Company” refer to SL Science Holding Limited, a Cayman Islands exempted company, and its consolidated subsidiaries. References to our “management” or our “management team” refer to our officers and directors. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with …

6-K · 2026-10-26 · 0001104659-26-118805

Read attachment ↗
tm2626021d1_ex99-1.htm · 6-K · 2026-09-24

Exhibit 99.1 The Nasdaq Stock Market, Inc. D: +852 3656 6054 Listing Qualifications E: nathan.powell@ogier.com 9600 Blackwell Road Rockville, MD 20850 United States of America ────────────────────────────────────────────────────────────────────────────── D: +852 3656 6061 E: florence.chan@ogier.com …

6-K · 2026-09-24 · 0001104659-26-110392

Read attachment ↗
tm2620209d1_ex99-1.htm · 6-K · 2026-07-10

Exhibit 99.1 SL Science Holding Limited Submits Orphan Drug Designation Request to the U.S. FDA for GDT Cell Therapy Targeting Glioblastoma Taipei, TAIWAN, July 10, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that the Company has submitted an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administra…

6-K · 2026-07-10 · 0001104659-26-082459

Read attachment ↗
tm2617928d1_ex99-1.htm · 6-K · 2026-06-15

Exhibit 99.1 SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market June 12, 2026 14:51 ET | Source: SL Science Holding Limited Post-combination company, SL Science Holding Limited, to commence trading on the Nasdaq Stock Market under the ticker symbol “SLBT” Transaction provides strategic capital to advance proprietary Gamma delta T cell-based "off-the-shelf" cellular therapies for solid tumor indications, in…

6-K · 2026-06-15 · 0001104659-26-073797

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.